v3.19.3
Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (Unaudited) - USD ($)
$ in Thousands
Preferred Stock [Member]
Series A Redeemable Convertible Preferred Stock [Member]
Preferred Stock [Member]
Series B Redeemable Convertible Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance (in shares) at Dec. 31, 2017 2,034,548 1,833,387 701,808      
Balance at Dec. 31, 2017 $ 12,814 $ 15,897 $ 1 $ 438 $ (31,294) $ (30,855)
Stock-based compensation expense 75 75
Net loss (1,523) (1,523)
Balance (in shares) at Mar. 31, 2018 2,034,548 1,833,387 701,808      
Balance at Mar. 31, 2018 $ 12,814 $ 15,897 $ 1 513 (32,817) (32,303)
Balance (in shares) at Dec. 31, 2017 2,034,548 1,833,387 701,808      
Balance at Dec. 31, 2017 $ 12,814 $ 15,897 $ 1 438 (31,294) (30,855)
Net loss           (4,451)
Balance (in shares) at Sep. 30, 2018 2,034,548 1,833,387 701,808      
Balance at Sep. 30, 2018 $ 12,814 $ 15,897 $ 1 663 (35,744) (35,080)
Balance (in shares) at Mar. 31, 2018 2,034,548 1,833,387 701,808      
Balance at Mar. 31, 2018 $ 12,814 $ 15,897 $ 1 513 (32,817) (32,303)
Stock-based compensation expense 75 75
Net loss (1,422) (1,422)
Balance (in shares) at Jun. 30, 2018 2,034,548 1,833,387 701,808      
Balance at Jun. 30, 2018 $ 12,814 $ 15,897 $ 1 588 (34,239) (33,650)
Stock-based compensation expense 75 75
Net loss (1,505) (1,505)
Balance (in shares) at Sep. 30, 2018 2,034,548 1,833,387 701,808      
Balance at Sep. 30, 2018 $ 12,814 $ 15,897 $ 1 663 (35,744) (35,080)
Balance (in shares) at Dec. 31, 2018 2,034,548 1,833,387 701,808      
Balance at Dec. 31, 2018 $ 12,814 $ 15,897 $ 1 747 (37,279) (36,531)
Stock-based compensation expense 84 84
Net loss (2,462) (2,462)
Balance (in shares) at Mar. 31, 2019 2,034,548 1,833,387 701,808      
Balance at Mar. 31, 2019 $ 12,814 $ 15,897 $ 1 831 (39,741) (38,909)
Balance (in shares) at Dec. 31, 2018 2,034,548 1,833,387 701,808      
Balance at Dec. 31, 2018 $ 12,814 $ 15,897 $ 1 747 (37,279) (36,531)
Net loss           (9,033)
Balance (in shares) at Sep. 30, 2019 5,807,877      
Balance at Sep. 30, 2019 $ 6 35,244 (46,312) (11,062)
Balance (in shares) at Mar. 31, 2019 2,034,548 1,833,387 701,808      
Balance at Mar. 31, 2019 $ 12,814 $ 15,897 $ 1 831 (39,741) (38,909)
Stock-based compensation expense 84 84
Net loss (4,676) (4,676)
Conversion of convertible notes and accrued interest into convertible preferred stock (in shares) 367,041      
Conversion of convertible notes and accrued interest into convertible preferred stock $ 3,203
Recognition of beneficial conversion feature upon conversion of convertible notes $ 2,101
Conversion of convertible preferred stock into common stock (in shares) (2,034,548) (2,200,428) 4,234,976      
Conversion of convertible preferred stock into common stock $ (12,814) $ (21,201) $ 4 34,011 34,015
Issuance of common stock for merger (in shares) 854,017      
Issuance of common stock for merger $ 1 5,246 5,247
Equity issuance costs paid in stock (in shares) 17,076      
Equity issuance costs paid in stock
Exchange of warrants 234 234
Dividend   (5,245)
Dividend       (5,245)    
Spin-off of AquaMed (1) (1)
Balance (in shares) at Jun. 30, 2019 5,807,877      
Balance at Jun. 30, 2019 $ 6 35,160 (44,417) (9,251)
Stock-based compensation expense 84 84
Net loss (1,895) (1,895)
Balance (in shares) at Sep. 30, 2019 5,807,877      
Balance at Sep. 30, 2019 $ 6 $ 35,244 $ (46,312) $ (11,062)